{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T05:14:37Z","timestamp":1778044477957,"version":"3.51.4"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T00:00:00Z","timestamp":1602201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"DOI":"10.3389\/fcell.2020.577215","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T07:26:05Z","timestamp":1602228365000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro"],"prefix":"10.3389","volume":"8","author":[{"given":"Godefridus J.","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank P. A.","family":"van Gemert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ietje","family":"Kathmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guru","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia A. G. M.","family":"Cillessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1158\/1078-0432.ccr-06-1754","article-title":"A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.","volume":"13","author":"Azzoli","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-61779-080-5_34","article-title":"Analysis of drug interactions.","volume":"731","author":"Bijnsdorp","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.bcp.2010.05.009","article-title":"Accumulation of thymidine-derived sugars in thymidine phosphorylase overexpressing cells.","volume":"80","author":"Bijnsdorp","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/1479-5876-5-49","article-title":"The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo.","volume":"5","author":"Buckley","year":"2007","journal-title":"J. Transl. Med."},{"key":"B5","first-page":"1925","article-title":"Antitumor activity of ZD1694 (Tomudex) against human head and neck cancer in nude mouse models: role of dosing and schedule and plasma thymidine.","volume":"3","author":"Cao","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/mc.22024","article-title":"Growth inhibition of pancreatic cancer cells by histone deacetylase inhibitor belinostat through suppression of multiple pathways including HIF, NFkB, and mTOR signaling in vitro and in vivo.","volume":"53","author":"Chien","year":"2014","journal-title":"Mol. Carcinog."},{"key":"B7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1182\/blood-2007-04-085480","article-title":"Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP positive diffuse large B-cell lymphoma cells.","volume":"111","author":"Cillessen","year":"2008","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bcp.2011.10.009","article-title":"Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.","volume":"83","author":"De Wilt","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1021\/jm00067a020","article-title":"Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin.","volume":"36","author":"DeGraw","year":"1993","journal-title":"J. Med. Chem."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-226","article-title":"Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.","volume":"12","author":"Dovzhanskiy","year":"2012","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs.","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1080\/10428194.2019.1612061","article-title":"Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate.","volume":"60","author":"Foss","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1123-1","article-title":"Folate receptors and transporters: biological role and diagnostic\/therapeutic targets in cancer and other diseases.","volume":"38","author":"Frigerio","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","article-title":"Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.","volume":"15","author":"Gonen","year":"2012","journal-title":"Drug Resist. Updat."},{"key":"B15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-3-319-13150-4_12","article-title":"Current management of peripheral T-cell lymphomas.","volume":"165","author":"Gooptu","year":"2015","journal-title":"Cancer Treat Res."},{"key":"B16","first-page":"711","article-title":"Differential effects of PXD101 (belinostat) on androgen- dependent and androgen-independent prostate cancer models.","volume":"40","author":"Gravina","year":"2012","journal-title":"Int. J. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/cad.0b013e3283300a0f","article-title":"A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.","volume":"20","author":"Hwang","year":"2009","journal-title":"Anticancer Drugs"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20687","DOI":"10.1074\/jbc.m802812200","article-title":"The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation - RFC as a double edged sword in folate homeostasis.","volume":"283","author":"Ifergan","year":"2008","journal-title":"J. Biol. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/s0065-2571(96)00012-x","article-title":"Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and resistant leukemia cells.","volume":"37","author":"Jansen","year":"1997","journal-title":"Adv. Enzyme Reg."},{"key":"B20","doi-asserted-by":"crossref","first-page":"18272","DOI":"10.1016\/S0021-9258(17)44748-X","article-title":"Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates.","volume":"265","author":"Jansen","year":"1990","journal-title":"J. Biol. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/0006-2952(94)90128-7","article-title":"Leucovorin rescue of human cancer and bone marrow cells following edatrexate or methotrexate exposure.","volume":"47","author":"Jolivet","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/0277-5379(91)90142-z","article-title":"Comparison of the sulforhodamine b protein and tetrazolium (mtt) assays for in vitro chemosensitivity testing.","volume":"27","author":"Keepers","year":"1991","journal-title":"Eur. J. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.18632\/oncotarget.27516","article-title":"The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma.","volume":"211","author":"Kinahan","year":"2020","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1634\/theoncologist.2017-0524","article-title":"Recent advances in the treatment of peripheral T-Cell lymphoma.","volume":"23","author":"Laribi","year":"2018","journal-title":"Oncologist"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2008-04-150276","article-title":"A novel loss-of-function mutation in the proton-coupled folate transporter from a patient with hereditary folate malabsorption reveals that Arg 113 is crucial for function.","volume":"112","author":"Lasry","year":"2008","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.1158\/1078-0432.ccr-12-2251","article-title":"Pralatrexate pharmacology and clinical development.","volume":"19","author":"Marchi","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1158\/1078-0432.ccr-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in vitro and in vivo models of T-cell lymphoid malignancies.","volume":"14","author":"Marchi","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-017-3473-8","article-title":"The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.","volume":"81","author":"Matherly","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00280-008-0683-0","article-title":"Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo.","volume":"62","author":"Mauritz","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0006-2952(01)00824-3","article-title":"Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.","volume":"63","author":"Mauritz","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/jco.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/15257770.2014.894196","article-title":"Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment.","volume":"33","author":"Peters","year":"2014","journal-title":"Nucl. Nucl. Nucleic Acids"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/ijc.23243","article-title":"Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer.","volume":"122","author":"Qain","year":"2008","journal-title":"Int. J. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/jto.0b013e318191520c","article-title":"Phase II study of Belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma.","volume":"1","author":"Ramalingam","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"125","DOI":"10.4137\/CMT.S3778","article-title":"Current and emerging therapies in peripheral T-cell lymphoma: focus on pralatrexate.","volume":"3","author":"Reungwetwattana","year":"2012","journal-title":"Clin. Med. Insights Therap."},{"key":"B36","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from non-Hodgkin\u2019s lymphoma classification project.","volume":"13","author":"Rudiger","year":"2002","journal-title":"Ann. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/0006-2952(94)90103-1","article-title":"Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity.","volume":"48","author":"Schmitz","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.bjc.6606063","article-title":"Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.","volume":"104","author":"Serova","year":"2011","journal-title":"Br. J. Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/14656566.2013.770474","article-title":"Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma.","volume":"14","author":"Shimanovsky","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"B40","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","article-title":"The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin\u2019s lymphoma.","volume":"12","author":"Tonner","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B41","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4161\/cbt.25941","article-title":"A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma.","volume":"14","author":"Tula-Sanchez","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/art.24219","article-title":"Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients.","volume":"60","author":"van der Heijden","year":"2009","journal-title":"Arthrit. Rheum."},{"key":"B43","first-page":"3675","article-title":"Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors.","volume":"61","author":"Van der Wilt","year":"2001","journal-title":"Cancer Res."},{"key":"B44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.lungcan.2013.05.014","article-title":"The role of epigenetics in malignant pleural mesothelioma.","volume":"81","author":"Vandermeers","year":"2013","journal-title":"Lung Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061664","article-title":"Roles of histone deacetylases and inhibitors in anticancer therapy.","volume":"12","author":"Verza","year":"2020","journal-title":"Cancers"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s00280-014-2441-2449","article-title":"The impact of 5-formyltetrahydrofolate on the anti-tumor activity of pralatrexate, as compared to methotrexate, in HeLa cells in vitro.","volume":"73","author":"Visentin","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a Novel Anti-Folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"B48","first-page":"3795","article-title":"Functional activity of the reduced folate carrier in KB, MA104 and IGROV-I cells expressing folate-binding protein.","volume":"55","author":"Westerhof","year":"","journal-title":"Cancer Res."},{"key":"B49","first-page":"459","article-title":"Carrier- and receptor-mediated transport of folate antagonists targeting folate-depending enzymes. Correlates of molecular-structure and biological activity.","volume":"48","author":"Westerhof","year":"","journal-title":"Mol. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.det.2015.05.009","article-title":"Methotrexate and pralatrexate.","volume":"33","author":"Wood","year":"2015","journal-title":"Dermatol. Clin."},{"key":"B51","first-page":"3235","article-title":"Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514.","volume":"18","author":"Worzalla","year":"1998","journal-title":"Anticancer Res."},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00486","article-title":"Histone deacetylase inhibitors to overcome resistance to targeted and immuno therapy in metastatic melanoma.","volume":"8","author":"Yeon","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399409000969","article-title":"Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues.","volume":"11","author":"Zhao","year":"2009","journal-title":"Expert Rev. Mol. Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1124\/mol.108.045443","article-title":"The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier.","volume":"74","author":"Zhao","year":"2008","journal-title":"Mol. Pharmacol."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.577215\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T06:44:36Z","timestamp":1617777876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcell.2020.577215\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,9]]},"references-count":54,"alternative-id":["10.3389\/fcell.2020.577215"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2020.577215","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,9]]},"article-number":"577215"}}